COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors (IMGN-0401)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01609556
Recruitment Status : Unknown
Verified June 2018 by ImmunoGen, Inc..
Recruitment status was:  Active, not recruiting
First Posted : June 1, 2012
Last Update Posted : June 7, 2018
Information provided by (Responsible Party):
ImmunoGen, Inc.

Brief Summary:
The purpose of this study is to test IMGN853 in patients with FOLR-1 positive tumors.

Condition or disease Intervention/treatment Phase
FOLR-1 Positive Solid Tumors Drug: IMGN853 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 205 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Study Start Date : May 2012
Actual Primary Completion Date : April 2018
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: IMGN853 Drug: IMGN853
Dose escalation study. Dosing on day 1 of every 21 day cycle.

Primary Outcome Measures :
  1. Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of IMGN853 [ Time Frame: During study ]

Secondary Outcome Measures :
  1. Evaluate the safety and tolerability of IMGN853 [ Time Frame: During the study ]
  2. Characterize the pharmacokinetics of IMGN853 [ Time Frame: During the study ]
  3. Assess IMGN853 pharmacodynamic activity [ Time Frame: During the study ]
  4. Characterize the immunogenicity of IMGN853 [ Time Frame: During the study ]
  5. Describe any preliminary evidence of IMGN853 antitumor activity [ Time Frame: During the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Criteria for Selection of Patient Population Inclusion Criteria

  • Patients with advanced solid tumor that is refractory to standard treatment, for which no standard treatment is available, or the patient refuses standard therapy.
  • ≥ 18 years old at the time of informed consent.
  • ECOG Performance Status 0 or 1.
  • Patients must have adequate hematologic and organ function.
  • Patients must be willing and able to sign the informed consent form, and to follow the study visit schedule and other protocol requirements.
  • Women of childbearing potential and men must agree to use effective contraceptive methods while on study and for at least twelve weeks after the last dose of study drug.
  • Women of childbearing potential must have a negative pregnancy test prior to the first dose of study treatment.

Exclusion Criteria

  • Grade >1 neuropathy
  • Any active or chronic corneal disorder and Sjogren's syndrome.
  • Serious concurrent illness:
  • Any other concomitant anti-cancer treatment.
  • Women of childbearing potential who are pregnant or breast feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01609556

Layout table for location information
United States, Kansas
University of Kansas Medical Center Research Institute
Fairway, Kansas, United States, 66205
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02062
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
United States, Oklahoma
University of Oklahoma Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United States, Texas
CTRC at the University of Texas Health Science Center
San Antonio, Texas, United States, 78229
Canada, Ontario
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
McGill University Health Centre
Montreal, Quebec, Canada, H4A3J1
Sponsors and Collaborators
ImmunoGen, Inc.
Layout table for additonal information
Responsible Party: ImmunoGen, Inc. Identifier: NCT01609556    
Other Study ID Numbers: IMGN853-0401
First Posted: June 1, 2012    Key Record Dates
Last Update Posted: June 7, 2018
Last Verified: June 2018
Keywords provided by ImmunoGen, Inc.:
FOLR solid tumors